Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Goodwin Lawyers Provide Updates on Biosimilar Litigation (<i>The Center for Biosimilars</i>)

main

12_27 FEATURE Goodwin Lawyers Provide Updates

FEATURE: Goodwin Lawyers Provide Updates on Biosimilar Litigation <i>(The Center for Biosimilars)</i>

Goodwin Lawyers Provide Updates on Biosimilar Litigation (The Center for Biosimilars)

Related Content

The Long (Un)Winding Road: FDA Maps Out How the End of the Public Health Emergency Will Impact its COVID-19 Policies

A Recap of Resilience: Goodwin’s Life Sciences Practice

CMS Issues Proposed Guidance on Inflation Rebates Under Medicare Part B

CMS Issues Proposed Guidance on Inflation Rebates Under Medicare Part D

340B Drug Pricing Program Reform Considerations

Top 5 Compliance Issues for Medtech Firms Transitioning To Data-Enabled Solutions (MedCity News)

Implications of Abortion Laws for Fertility Services

Congress Expands Pathway for Drug & Device Manufacturers’ Pre-Approval Communication of Health Care Economic Information to Payors, Formularies, & Similar Entities

Abortion Pill Ruling Looms Over FDA's Drug Approval Process (Axios)

Abortion Pill Court Docket Delay Concerns Legal Advocates (Bloomberg Law)

BridgeBio Pharma Announces Pricing of Public Offering of Common Stock

Abortion Pill, Vaccine Attacks Spell Trouble for FDA Approvals (Bloomberg Law)

Access to Abortion Pills at Risk in US as Judge Weighs ‘Unprecedented’ Case (Financial Times)

Goodwin Represents the Placement Agent on ImmunityBio’s $50.0 Million Offering

Fulcrum Therapeutics Closes $125 Million Public Offering of Common Stock

Top 5 FDA Considerations for Medtech-Enabled Data Platforms (MedCity News)

Life Sciences

Life Sciences Regulatory & Compliance

Patent Trial & Appeal Board

Hatch-Waxman, Biologics and Biosimilars Litigation